Faster-recruiting clinical sites
Sites chosen against competitor trial footprints, not generic performance lists, so you recruit where rivals aren't already competing for the same patients.
Approval wins the launch.Intelligence wins the decade.
Most oncology programs are designed to get approved. Few are designed to still lead ten years later. AmethIntel connects scientific, clinical, competitive, regulatory and commercial signals into one knowledge graph, and shows you where your leadership is exposed before a competitor finds it.
From approval to a decade of leadership
Each pillar is a decision made years before a fast follower arrives.
- Approval is where the crossing starts.
- Trial design that makes the next entrant's trial harder.
- IP & diagnostics built as layered barriers.
- AmethIntel intelligence lighting the whole route.
- Longitudinal RWE that extends the evidence past the pivotal trial.
- Clinical sites chosen against competitor footprints.
- Leadership plan that carries the program to 10-year category leadership.
Three questions that decide who leads
- Is your trial built only to win approval, or also to make the next entrant's trial harder?
- Where are the incumbent's gaps, and who else has already seen them?
- Will your IP and diagnostics strategy still hold when fast followers arrive?
The answers decide whether you lead the category, or become someone else's opportunity.
Flagship case studyProof: CEACAM5
A full competitive, clinical and diagnostic landscape of CEACAM5, a crowded antibody-drug conjugate target in solid tumors.
44programs mapped
187clinical trials analyzed
The study uncovered subtle changes to clinical trial designs that improve the chances of holding leadership for ten years after approval.
From the AmethIntel CEACAM5 report, by Akash Mathur PhD MBA and Gregory Schneider PhD
What the intelligence lets us do for you
Each service starts from the same connected map of trials, assets, patents and partners, so the advice reflects the whole landscape, not one slice of it.
Longitudinal real-world evidence
Real patient trajectories that ground strategy and extend the evidence base well beyond the pivotal trial.
IP, publication and narrative strategy
Patents, publications and positioning built as one layered barrier, not separate workstreams that competitors can pick apart.
Partnerships and deal support
High-fit partners identified, proposals developed and agreements structured to protect long-term position, whether you're defending a category or entering one.
Takes Two to Tango
Strategies to increase the value of the asset by pooling fragmented datasets. Insights from Akash Mathur.